declin government money still maintain guid
report adj ep est/consensu adj oper incom adj
oi estimate us dialysi revenu roughli line est/consensu
treatment line consensu estimate rev/treat
est/consensu dva adj oi margin estimate patient
care cost/treat estimate a/treat line dva strong adj
oi includ benefit calcimimet expect taper
rest expect compar importantli
reiter guidanc indic despit signific extra cost
disrupt manag bullish sign declin
payment due care act still abl reaffirm
guidanc rais est beat rais po vs prior
reflect better resili covid reit buy rate given stabil
vol cap deploy opportun backdrop normal
mix import recess see impact yet
due rate differenti commerci insur medicar rest
payer biggest impact recess shift payor mix
said hasnt see neg impact payor mix yet slightli
intern expect compani confid larg portion
unemploy number furlough even patient lose job
addit coverag option exchang cobra mitig neg
organ growth tick sequenti
dva non-acquir treatment growth slow recent vs
prior see modest q/q improv y/i vs
vol continu modest improv
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
davita inc lead dialysi provid
unit state compani oper
outpati clinic us serv
patient also oper countri
outsid us
healthi balanc sheet aid sale dmg
combin strong allow
signific capit deploy next coupl
year headwind exist
pandem abil repurchas
share stabil ep look like
year reacceler growth given potenti
growth medicar advantag
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
po base ebitda estim upper end
stand-alon histor rang ebitda justifi view
due defens natur dialysi provid tailwind patient
shift medicar advantag medicar ff higher reimburs
upsid risk po commerci mix better expect
reimburs better expect make chang third
downsid risk po commerci price pressur return ss treatment
growth rebound wors expect headwind calcimimet
ballot initi larger expect disrupt
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
